Update 7/30 Hologic (HOLX) Beats by $0.03 beats on revenues: stock up 3.2% AH to $26.80. Hologic Announces Third Quarter Fiscal 2014 Operating Results | Seeking Alpha Update 7/29 Rally Is Cut Short By New Sanctions On Russian Industry-Sell-Off at 2:15 EDT Consumer Confidence at 90.9 vs Forecasts 85.0-Before Market Opens Diagnostics/Tools stocks trying to rally […]
Healthcare Stocks trail other sectors up 0.34%, Energy up 0.8%, Financials up 0.73% and Technology up 0.77% But biotech ETFs are in the Green Biotechnology stocks were mixed today with the following winners among our large cap picks: Gilead Sciences (GILD) up 1.26%, Roche Holding (RHHBY) up 1.08% and Regeneron up 0.58%. Our large cap […]
Rayno Life Science Stocks Focused on Genetic Tests and Biomarkers We have been writing about molecular diagnostics and tools stocks for over 5 years. Here is the summary of our Portfolio. Yesterday we provided an update from BIO 2014 on personalized medicine and genetic tests. Many genetic tests are not FDA approved usually called LDTs […]
Rally Retraces Correction Up To Mid-Point YTD Up until this week we have focused on large cap biopharmaceuticals because of revenue momentum, fair valuations and earnings. A risk -off sentiment due to lack of ASCO buzz and the Q1 speculative bubble downdraft has curbed gains. This week with news of the Merck $3.9B deal for […]
Clinical Diagnostic Stocks Were Hit By Bio-Bubble or Revenue Miss Potential upside in EXAS, NSTG and NEOG all are Rayno Dx and Tools picks. With “momentum trading” days over for now, revenue growth is the focus. Companies with disappointing Q1 revenues: Abaxis (ABAX), Alere (ALR), Response Genetics (RGDX) and Quidel (QDEL). Q2 recovery will be key. […]
Caution As Life Science Stocks Are Consolidating Life science stocks had a wild roller coaster ride in 2014 with many stocks peaking around March 1. Momentum and cult stocks in our portfolio still had a good quarter with the following top winners: Illumina (ILMN) up 25.2%, Vermillion (VRML) up 25%, Exact Sciences (EXAS) up 21% […]
